Cimetidine and the Immuno-Response in Health Volunteers  by Brockmeyer, Norbert H. et al.
Cimetidine and the Immuno-Response 
in Healthy Volunteers 
Norbert H . Brockmeyer, M.D. , Ernst Kreuzfelder, Ph.D. , Wolfgang Guttmann, M.D., Lutz Mertins, M.D., 
Manfred Goos, M.D., and Edgar E. Ohnhaus, M.D.' 
Dep;artmcllLs of I)(,rm .. tology (NHB. LM. MG), Medical Vi ro logy .;and Immllnology (EK, WG), and Int('rnal Medicine (REO). 
University of Essen. Federal Republic of Germany 
We compared the immunologic measurements from treat-
ment of 12 healthy volunteers (six male, six female) with 800 
and 1,600 mg cimeridine. In the nrst trial 800 mg cimctidine 
was adminis[, ' !d daily to the vol unteers over a period of 7 d; 
after an in tel 'prion of 2 months. 1,600 mg of cimetidinc 
was applied ai ly for 21 d. 
The m Ost st riking result of our study was an increased 
mitogen-in·J,jced lymphocyte proliferation. This conclusion 
can be dra" II from the fact that phytohaemagglutinin (PHA) 
(0.4 Jig/well) and pokeweed mitogen (PWM) (0.4 Jig/well) 
induced lymphocyte proliferation were found to be signifi-
cantly increased in comparison to pretreatment values on day 
7 in borh cimetidine regi mens (800 mg: PHA: mean prolifer-
ation 66,500 before treatment to 166,000 epm. PWM: mean 
proliferation 8,800 before treatment to 34,000 cpm: 1,600 
mg; PHA: mean proliferation 48,700 before treatment to 
81 ,600 cpm: PWM: mean proliferarion 6,300 before treat.-
ment to 16,200 cpm). 
Increased mitogen-induced proliferation following cime-
tidine intake is of special i.ntcrcst becausc the mechanisms of 
this activa tion process are incompletely known. Lymphocyte 
proliferation response is dependent on the avaiJabiliry of ex-
T he activation and proliferation of T and B lympho-cytes is guided by intracellular 5i nal systems. in which calcium cations participate [11. Besides the ac-tion of calcium al ready memioned. there seem to be other divalent cations involved in the m('chanisms 
leading to proliferation. As Winchurch f2] showed, zinc (Zo) does 
nOt only enhance the 10 vitro proliferation responses of murine 
rhymocyrcs activated by phytohemagglutinin (PHA) but can also 
prime ce lls to respond early to in terleukin-l without PHA activa-
tion. Magnesium (MS) seems to have an effect on proliferation 
synergiS[ical to that of calcium. This was shown by Abboud Ct al [3] 
who measured concanavalin A (Con A) and PHA-induced prolifera-
tion of lymphocytes. 
In previous studies with healthy volunteers treated with 800 mg 
and with H IV 1 infected patients treated widl 1.200 mg of the 
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tracellular calcium. The func tion of the other bivaJent cat-
ions is unknown. We found that the extent of mitogen-in-
duced lymphocyte prOliferation correlates with cellular 
intra lymphocytic zinc and magnesium amounts (coefficients 
of correlation lr]) (800 mg: PHA/ M& r = 0.84: PHA/ Zn 
r = 0.86; PWM/ Mg r = 0.88; PWM/ Zn r = 0.87). 
Though tho application of borh cimetirune doses causes 
enhanced mitogen-induced lymphocyte proliferation on day 
7, T lymphocyres with different phenorypic properties ap-
pear to be influenced by cimetidine. In the first dose regimen 
(800 mg) the number of the CD8 lymphocytes decreased 
significantly from 16.1 % (365 cell/Ill blood) to 12.7% (264 
ce lls/ Jil blood) after 7 d of cimetidine intake. After the period 
of high-dose (1,600 mg) cimetidine administration (a t day 
21) numbers of CD4 lymphocytes were significantly in-
creased from 41. 5% (860 cells/Jil blood) to 56.3% (1,210 
celiS/ill blood). 
Our results show that although different cimiridine doses 
obviously influence different cell types of healthy volunteers, 
the cel lular mechanisms arc the same, namely. a proliferation 
and an increased incorporation of magnesium and zinc in 
lymphocytes. ] 1""cst Dermalol 93:757 - 761, 1989 
histami.ne H2-teceptor antagonist cirnetidine, we ohserved signs of 
immunologic activation 14.5). T herefore. we measured Mg and Zn 
amounts in lymphocytes in order to correlate the immunologic 
alterations with cellular levels ofMg and Zn. Further, we compared 
the immunologic measurements that arose from treatment in 
he-althy volunteers with 800 and 1.600 mg cimetidine. 
MATERIALS AND METHODS 
Volunteers 12 beal thy volunteers. six male and six fe male. ran g-
ing in age from 24 to 33, were investigated in this study. All volun-
tCeTS were informed about the aims of the study and g.ave their 
written consent. The ht"alth of the vo lunteers was checked before 
and after tht" study by means of a clinical and laboratory exami na-
tion. which incl uded cornpl et~ blood count; differen tial blood and 
platelet count; absolute gra nulocytcs and monocyrcs counr; serum 
analysis. including rotal protein, albumin, globulin. ca lcium, phos-
phorus. BUN, crea tinine. bilirubin. aJkaline phosphatase. lactic de-
hydrogenase. and serum glutamicoxaloacetic acid transa.minase~ and 
serum prmcin dccrrophoresis. 
Study Design During rhe first treatment period of 7 d, 800 mg 
cimeridint" was administered daily, in doses of200 mg in the morn-
ing. 200 m~:a lunchtime, and 400 mg in the evening before dinner. 
Venous blood samples were obtained at 8:00 a.m... 2 days before 
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Table 1. l ncreased Numbers of Pc:ripher3! Blood B 
Lymphocytes, C02 Lymphocytes, and Macrophages (CO l i b), as 
well as Serum Concentrations of Immunoglobulin G. A, and 
Complement Componenr C3 Fol.lowing Cimetidine Intak(, 
(1,600 mg d.y- ' during 21 d) in 12 H ealthy Volunteers 
Cdl ry~s. 
immunoglobul ins . Olnd Before 
complement cimetidillr inrake-
Cell rypes 
Leukocytes (cells nl- ') 6.7 ± 3.1 
Lymphocytes (%) 31.6 ± 8.3 
Lymphocytes (cd ls nl-') 2.0 ± 0.8 
B Lymphocytes (cett$ "I- I) 0.26± 0.1 
C02 (%) 69.5 ± 6.0 
CD2 (cells nl- ') 1.4 ± 0.6 
C03 (%) 64.0 ± 5.2 
C D3 (cells nl- 1) 1.3 ± 0.6 
CO llb (cdl> nl-') 0.09 ± 0.03 
Leu7 (%) 6.1 ± 3.8 
Leu7 (cells nl- ') 0.12 ± 0.06 
Immunoglobulins (1g) 
IgG (g dl- ') 1.1 ± 0.21 
IgA (g dr') 0. 17 ± 0.04 
IgM (g dl-') 
Complement 
0.13 ± 0.04 
Total (Titer) 142± 31 
C3 (mg dl - ') 98.6 ± 25.2 
C4 (mg dl-') 19.6 + 5.5 
• ll5U'd figurC'~ arc man :t. si-and:nd dc\, ,~tion . 
10 p <: 0.05. It'S Ir:d :lg;unsl v-aluc o( dly O. 
After 
cimetidine intOlkr 
7.7 ± 3.4 
33.3 ± 11.7 
2.6 ± 0.8 
O.:}41.± 0.1 
77.8b ± 6.2 
2.0" ± 0.6 
67.0 ± 6.2 
1.9 ± 0.5 
0.28" ± 0.08 
6.9 ± 3.7 
0.14 ±O.06 
1.3" ±0.25 
0.2()h ± 0.05 
0.15 ± 0.05 
147 ± 24 
lIS.7"± 16.7 
19.2+ 5.7 
starting the treatment (day 0) , during the- treatment (day!. 1, 2 and 
4), and after cimetidine intake (days 7 and 14). T here was a 2-d 
interval brrween the first blood sampling and cimctidine adminis-
tration bccOluse a skin-test was carried out on the same day (d.ay 0) 
and we did not want the results of the test to be influenced by 
cimecidine. 
Two months afte r the last cimeridine dosage (800 mg) blood was 
obtained again at 8:00 a.m. , and a skin-rest was carried OUl (dOly 0). 
Two days later 1.600 rng cimetidjne was applied in the same sub-
j ects in the SOlme WOly as in the first rrearment. During the cimetidine 
intake period blood was taken Ollce on d3.y 7 afrer cimetidine illtake. 
After the subjects had stopped taking cimctidine, blood samples 
were taken on days 21, 28. and 42 afrer cimetidine intake. 
Isolation of tbe PBMC The isol.ation of the peripheral blood 
mononuclear cells (PBMC) was accomplished by using heparinized 
blood samples according to KIeuzfelder er a1 [6]. In short. 1 ml 
verren® 200 plus 19 ml blood were layered ova Ficoll-Pague 
(Pharm.acia, Freiburg, FRG). After washing, the number of har-
vested PEMC was adjusted to 7.5 X 106 cells ml- I• Twenry micro-
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liters of this cell suspension was then incubated for 60 min at 4 DC 
together with 20 pi of each of the selected monoclonal wtibodies. 
The- foll owing monoclonal antibodies (Ortho Diagnostic Systems, 
NeckargemOnd. FRG) were selected for .definition ofT cell pheno-
rype and used in I : 15 dilution in 20 j.d volumes: CD2 and CD3 
(tocal T-Iymphocyte population), C04 (helper l induce r T Iympho-
cyt(" subset), CDS (cytoroxic/ suppressor T -lymphocyte subset), and 
C Dl1b (macrophages/ monocytes). Natural killer cells were la-
beled using the monoclonal antibody Leu 7 from Becton Dickinson 
GmbH (Heidelberg. FRG). Following rhe initial incubation phase 
wi th the primOlry antibody the cd Is were washed and incub:ned for 
60 min at 4 DC with a fluoresceine isothiocyanate conjug::r.tcd 
(FITC) goat ami-mouse immunogl,obulin (Med3.c. Hamburg, 
FRG). Tht" labeled cdls were analyzed by single color fl ow cytom-
erry (Epics C. Coul ter Electron ics, Hialeah , U.S.A.). For each sam-
ple, 5,000 cells were analyzed on :l; lineal" fluorescence scaJe. 
Relarive' B lymphocyte numbers were detennined by staining rhe 
lymphocytes with polyvalent FIT C -Iabeled F(ab), fragment of 
anti-human immunoglobulin (Behring Werke AG, Frankfurt, 
FRG). The labeled cells were examined using a fluorescence micro-
scope (Zeiss. Oberkochem. FRG). Absolute cell numbers were cill-
culated from the leukocyte number (Coulter) and the relative num-
ber of lymphocytes derived from a differemial blood smear. 
Lymphocyte Proliferation Lymphocyte proliferOltion assays 
were performed as described 17], 0.2 tnl of the abovc memioned cdl 
suspension (7.5 X 106 cells ml-
'
) was transferred into a microtiter 
plare (GA. Greiner & Sbhne GmbH & Co KG, Nurtingen, FRG) 
and 20 pI mitogen was added. Mirogcns (Sigma C hemic GmbH, 
Deisenhofen , FRG) were used in the following final concentra-
tions: Con A at 2pg ml- ' , PHA and PWM at 0 .4 pg ml-
'
. All tests 
were performed as quadruplicate samples and incub:ued ar 37 D C in a 
humidified atmosphere of air (95%) and CO, (5%) for 72 h. In 
order to evaluate mitogen- induced proliferation. l llCi oP H-meth-
ylthymidinc (Amt'rsh::un Buchler, Braunschweig. FRG) was added 
for the final 4 h of rhe culturing procedure. Thereafter, PBMC were 
harvested on glass nber filters (Dunn Labortechnik. Asbach. FRG) 
by using a titcrtck (Skacron GmbH, Dusseldorf. FRG) and cOllnted 
with 5 ml scin tillation fluid (Uniso lve I. Zinsser Anaiytik GmbH. 
Frankfurt, FRG) in a beta-scintill<ltions counter (KomIon. Mun-
chen . FRG). 
Zinc and Mag nesium Amounts Zn and Mg amounts in lym-
phocytes were measured using tilt: above~menrjoned ce ll suspen-
sion, which after glass fiber sep.aration contained > 95% lympho-
cytes; the remaining cd ls were monocytes and neuc rophils. 
D~terminations were carried out by means of atomic-absorption 
spectrophotometry (Perkin & Elmer model 300 S. Dberlingen, 
FIlG) afrer using the wet ash technique with instra-analyzed nitric 
acid 18J. Each s<lmple (50,u1) was measured in guadruplicate. 
C omplement and Immunoglo bulins Concentrations of com-
piemem compollenrs (C3. C 4) and immu noglobulins (lg)A. G. M 
Table D. Increased N umbers of Peripheral Blood CD8 Lymphocytes as well <IS Values of CD4/ CD8 Ratio and Total Score of Skin 
Test Following Cimetidine Intake (800 mg day- I du ring 7 d) in 12 Healthy Volunteers 
C imeridine intake Day (Cells nJ- ') 
Before 0 0.942±0.142 
During I 0.S50 ± 0.121 
During 2 0.879 ± 0.115 
During 4 0.S74 ± 0.138 
After 7 O.990±0.123 
After II 0.972 + 0. 149 
~ Lilted figur('~ arc mt'~n) ± sun.hrd dcviltiQn. 
10 n.d.; nOt done . 
• p < 0.05. [eSlr:d ~gllDn v~lue of dly O. 
~ P < 0.0 1. tCSlcG ~gainn nluC' of d~y O. 
CD4" 
(%) 
42.91 ± 2.S7 
42.90 ± 3.19 
40.45 ± 2.99 
41.09 ± 3.30 
44.82 ± 3.30 
44.09 ± 2.6' 
CDS' 
Total Kore or CD" /COS' 
(Cells ,,1- ') (%) cel l r:.ltio skin tesf' (mm) 
0.365 ± 63 16.09 ± 2.00 3. 15 ± 0.50 13.S ± 4.3 
0.298 ± 46 15.09 ± 2.08 3.53 ± 0.67 n.d." 
0.307 ± 38 14.36 ± 2.49 3.73 ± 0.67 n.d." 
0.302 ± 42 15.45 ± 2.02 3.43 ± 0.76 n.d ." 
O.264e± 64 12.70' ± 2.58 5.00' ± 1.14 24.S' ± 5.9 
0.288 ± 53 13.73 ± 2.01 ' .09 ± 0.80 n.d." 
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Table m . Increased Numbers of Peripheral Blood CD4 Lymphocytes Following Cimetidine Intake (1,600 mg day-l during 21 d) in 
12 Healchy Volunceers 
CD4~ 
C imctidine intake D,y (Coli, nl- ') 
Before 0 0.S60 ± 0.327 
During 7 0.999 ± 0.457 
During 21 1.21 0" ± 0.303 
A.ftcr 2B 1.373b ± 0.343 
After 42 1.053 ± 0.278 
• LlSced figurc~ ;m :: Inran ± standard deviation. 
~ p " 0.05. [CSled .againn valur of day O. 
• n.d.: 1101 dOl'le 
(%) 
41.5 ±S.7 
45.1 ± 8.9 
56.3b ± 9.8 
46.51> ± 9.3 
46.3 ± 8.9 
were dctcrmined by employing nephelometry (Array, Beckm:m 1n-
srrumencs GmbH . Mii nchen. FRG) [9J. The hemagglutination 
method was used to ascertain total complement. 
Delayed Hypersensitivity Skin Testing Delayed hypersensi-
tivity skin testing was applied on the forearm wieh the Mul tieest 
Skin T est Device (Merieux Institute. Norderstedt, FRG) which 
contains recall antigens via 8-tine multipuncture heads. T he skin 
test reaction was measured in millimeters as the total diameter of 
skin indurarion following rhe administration of trychophyton . can-
dida, tetanus, diphtheria, streptococcus, proteus, and tuberculin an-
tigen!>, as well as a glycerol control with a single stroke [10], The 
rotal score was determined after 48 h, 
Statistical Analysis For each time interval, mean and standard 
deviation were calculated for each parameter. T o asce rtain differ-
ences between the treated and untreated volunteers at one time 
point , Wilcoxon's two-sample rest was performed. In order to ex-
clude d~pendencies of repeated measurements in an individual, the 
median value- over time was calculated for each parameter and for 
each time; the median value was subtracted from every value: and 
differences were compared to the basic differences at day 0, e.g., 
before treatment level by using the Dunnett test. In order to test Zn 
and Mg amoums and mitogen-induced prolife ration for parallel 
cou rses , a cross-correlation test was carried our using SpeartJ1an's 
coefficient or corrf'iation. The level of significance was designated 
at 0' = 0.05 (rwo-tailed test). Statistics were performed using an 
IBM 4331 calculator undt'r VM/ SP employing the SAS software 
package. 
RESULTS 
No subjective or objective." side eftecrs were observed during {he 
periods of drug intake. 
The absolute number of macrophages (eD Ith). the relative 
numhcrofB lymphocytes, and the absolute- and relative numbers of 
CD2 cells. as well as concentrations of IgG, IgA, and C3. were 
increased significan tly only after the rust day of hi gh dose- (1.600 
rug) cimetidine cessation (day 21, Table I), 
In the first dose regimen (800 mg cimeridine) abso lute and rela-
tive numbers of rhe CD8 T cells decreased significanciy at day 7 
(Table ll ). According ly, the CD4/ CD8 cell ratio showed, signi6-
CDS" 
CD4'/CDS' 1" oul score of 
(Cells nl-') (%) cdl ratio skin test' (mm) 
0.356 ± 0.187 17.9±6.2 2.S±2.1 18.4 ± 4.S 
0.355 ± 0.205 17.1 ± 7.6 3.6 ± 2.B 21.9 ± 7.6 
0.393 ± 0.155 19.1 ± 5,6 2.9 ± 1.8 17.2±7.3 
0.592 ± 0.228 20.5 ± 5.8 2.6 ± 1.6 12.7 ± 5.5 
0.491 ± 0.241 20.S±7.9 2.6± 4.7 n.d .. 
cam increase from 3.2 to 5.0. Compared with low-dose therapy the 
CD4 lymphocytes changed by high-dose cirnetidine therapy and 
increased significantly at days 21 and 28 (T able In). 
Significantly enhanced PHA and PWM-induced lymphocyre 
proliferation were observed in both regimens at day 7 (Tables IV 
and V), whi le significant increases of Con A-induced proliferations 
at different times could be observed in cimetidine regimens. 
Skill tesc reactivity as measured in tocal score was signi6cantly 
increased only after [he first cirnetidine intake (Table II). 
T he maximum increase in cellular Zn and Mg amounts was ob-
served after 7 (800 mg cimetidine. T able VI ) and 21 d (1.600 mg 
cimetid ine, T able VU). Zn and Mg plasma levels remained un-
changed during and after both treatments, and mean v:alues were at 
75 ± 15 Jlg dl-' for Zn and at 2,100 ± 150 Jlg dl-' for Mg. The 
extent of mirogen-induced lymphocyte proliferation following oral 
cimetidine intake as well as Zn and Mg levels correlate with coeffi -
cients of correlation between r = 0.84 and r = 0.89. 
DISCUSSION 
The most strik.ing resuJr of our study was an increased PHA and 
PWM-induced lymphocyte. proliferation in healthy voluntee.rs 
treared with cimetidine. This conclusion can be drawn because 
PHA and PWM-induced prolife ration were the only immunologic 
paramercrs meas.ured that wen" found to be significantly increased at 
the same rime, that is, on day 7, in both cimetidine regimens. T his 
conclusion is supported by the fact that an enhanced cimetidine-in-
duced proliferation has also been found in studies in whkb different 
methods were employed, Gifford er aI [11] showed thar rhe in vitro 
PHA and PWM-induced proliferative response of lymphocytes 
fr.om. healthy individuals had augmemed significantly because of in 
vitro (reatmenf of PBMC wirh (lO-J to 10-8 M) cimetidine, or ro 
cimetidi ne containing serum [1 2]. Moreover, rhe treatment of pa-
tients with cimctidine involves a significant inctease in the propor-
tion of lymphocytes responding in vitro to PHA and Con A mea-
sllre-d by volume spectroscopy [13] or Con A measured by 
' H-rnethylthymidine uptake 114 J. 
Th(' observation of an enhancement of micogen-induced lym-
phocyte proliferation caused by cimeridine is of special intcrest. 
because rhe mechanisms of chis process are roughly k.nown. Thus. 
Table IV. Increased Mitogen-Induced Proliferation Measured as JH -methylrhymidinc Incorporation of Peripheral Blood Lymphocytes 
Following Cimetidinc Inrake (800 mg d during 7 d) in 12 Heal rh y Volunreers 
Cimetidine intake Day Con N (cpm 103) PHN (cpm 103) PWM' (cpm HP) 
Before 0 26.6 ± 7.2 66.5 ± 12.4 B.B ± 2.4 
Outing I 54.9 ± 11.3 142.7 ± 4S.5 12.5 ± 3.0 
During 2 39.9 ± I I.S 75.8 ± 17.2 13.3 ± 13.1 
During 4 64.9 ± 13.3 100.2 ± IS. ! 13.9 ± 3.1 
After 7 129.'1" ± 14.9 166.0" ± 15.7 34.()I>± 8.3 
After II 55.6 ± 15.0 105.5 ± 12.0 IS.2 ± 5.5 
• Peripheral blood mononllcicar cd l ~ w~re incuhat.ed with 2.uS of mitogcn c~nca~avalin ~ (Con A) ml- I O.~ Ilg phylOhenugglu6nin (PHA) rol . I, ~r O.4.ug pokeweed mitogen 
(PWM) 1Il1- I, and lH_Mcl h),lthynudinc incorporatIOn w,u meuured as dcscrlbed In M a//'f'III /'lfu/ M elltrnh. Listed ligures aTe meall ± stancb.rd dCYl2tlon. 
b p < 0.05, leSted :ltgaillSi v:ltluc of cU. )' O. 
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Table V. Increased Mi[Ogen-I~duce~ Pr~l ~ferarion Me3.Surc:d as 3H-mc:d1y'lthymidine Incorpof3tion of Pe.ripheral Blood Lymphocyres 
following Clfficndme Intake (1,600 mg day-I dunng 21 d) in 12 Hc:ahhy Volunteers 
Cimetidine intake Day Con A' (cpm 10l) PHA' (cpm t()l) PWM' (cpm IOJ) 
Beforr 0 27.1 ± 14.6 48.7 ± 19.0 6.3 ± 3.6 
During 7 48.0 ± 26.7 81.1" ± 38.5 16.21. ± 11.7 
During 21 83.21. ± 31.0 133.51. ± 62.0 18.'1' ± 7 .1 
During 28 59.2 ± 28.2 7 1.0 ± 25.0 15.2 ± 8.6 
After 42 25.2 ± 9.5 37.6 ± 28.7 7.0 ± 5. 1 
• PC"rlplu:r~t hlooJ mCll1ol1ucie-.u cells werc incumtro with I IJ.r,or mitogen conClonloV:...lin A (Con A) ml 1. 0.4 }.Ig pnYlonC:lII.agglutlllin (PHil.) mt- t • orO.4 Jlg pokt"wua mitogen 
(PWM) ml-'. ;and 'H-Mcthylthymldint' incorpor.Uton w ;u meuurro lo) described III Mllfff ials dnll M rfhrlds. Lislro hgures arc me;an ± stanwrd dt"\·j:l.llon. 
~ p < O.OS. IC5l('d ag;unn v.Jue of day O. 
conclusions can be drawn from our resulrs wirh rega.rd ro participa-
rion of cario ns in rhi s proccss and ro phenorypical properties of 
lymphocytes. 
In Iymphocytcs rhe capaciry of differenr mitogens to induce a 
proliferarive response is dcpendem o n the availability of exrracdlu-
lar calcium. Lymphocytes will not proliferarc wherher stimulated 
by amibodies specific for rhe T cell reccpror complex (TCR-CD3). 
or the C D2 teceptor, by Con A (TCR-CD3) and PHA (CD2). 
when the concentrarion of extracellular calcium is reduced to rhe 
nanomolar range. The funccions of other ru valent carions in rhe 
activarion parhways of human Iymphocyrcs are unknown. Recem 
srudies by Modiano er al PS) indicate that Mg can r('place calcium 
and rhus can produce an increased response in Iymphocyrcs follow-
ing FHA stimulation. This suggestS that there is a calcium-indepen-
dent, Mg-dcpendcnt step thar will lead ro lymphocyte proliferation. 
Our resulrs are in contrast (Q th is assumption because rhe extralym-
phocyric Mg amount is significandy enhanced later than PHA-in-
duced proliferarion because of 1,600 mg cimcridinc inrake. Thus, an 
alrcrnarive explanation by Modiano ct al [15] for the funcrion of 
divalent carions in the proliferation process becomes more likely: a 
nonspecific divalent ca rion cofacror (s) is necded in one or several 
reactions rhat take place early during the aerivation of lymphocyres 
by PHA. This argument is subsrantiated by rhe fact rhat signifi-
cantly enhanced Zn amounts were derected in lymphocytes at rh(' 
same time as Mg amounts following cimecidine inta k~. Although 
all scudies (concerning function of Zn++ in in virro lymphocyte 
responses) agree that Zn plays a certain part in in virro lymphocyte 
acti vation. its exact roJe needs to b~ darifi~d 116]. Our resules addi-
tionally provide indication with regard to the activation mecha-
nisms because at both cimetidine dosages: Mg and Zn were signifi-
cantly increased only in lymphocytes when Can A-induced 
proliferation was also significantly increased. Thus. it can be con-
cluded that " T cell receptor complex" (TCR-CD3) mediarcd acti-
vation leads to cnhanced uptake of" divalent carions" and nor CD2-
mediated activation. 
Though the:: application of both sao mg and 1.600 mg cimetidine 
doses ca.uscs enhance::d PHA and PWM-induced proliferation on 
day 7. T lymphocytes with differenr phenotypical properties appear 
ro he influenced by cimetidine. In agreement with the findings by 
White and Bellow [t 7J. we observed a decrease in CDBlymphocyte 
numbers and no al terarions of the number of CD4 cells following 
BOO mg cimetidine lntak.e. Although the leukocyte and lymphocyte 
numbers were unaltered, rhe absolute and rclarive numbers ofCDB 
cel ls were significantly dim.inished. This means that this effect is 
probably a true effect. because the error of measurement of the 
absolure number is greater rhan the error of measurement of rhe 
relarive numbers {IBl. 
The effect of cimeridine. in reducing rhe number of COB cells. 
may be modulating the expression of the C OB antigen or lysis of 
these cells. We do nor know what bappens here; however. it seems 
more reasonable to assume ~ modularing effect of [his drug, because 
shortl y after the end of drug administration C D 8 cell numbers 
reach the starting value. Ir is reasonable to posruiac(' rhat a (Hmin-
ishcd number of CDB cells means a decreased suppressor function 
It 9]. However. the proporrional clearance in CDB ce lls is less rhan 
the increase in lymphocytes reacrivity. and the concept of suppres-
sor cell funcrion bas recently been Gucstioned 120J. Therefore. it can 
be suggested thar {he result of cimeridine intake is a rdative domi-
nanCt" of T helper lymphocyrcs. as is clearly shown in patienrs tak-
ing 1.600 mg of cimeridi.ll c. 
Suppression is associated nO{ only wirh C OB hUi with rhe C D4 
Iymphocyres and especially wirh C D4 subset C D45R-cdls. which 
hav(' only rc:cendy been characrerized 121]. As neither number nor 
funcrio n of this subpopularion of C D4 T lymphocytes has been 
detcnnined to be connected with cimeridinc effect. rhe mechanism 
of histamine-induced suppress ion is nOt completely understood. 
The r('larive dominance of CD4 cel ls may reflecr systemic aC(iva-
tion of rhe immune system. Indeed. Our results support the: systemic 
immune system acrivarion. First, significan tly increased prolifera-
rio n following activation by mitogens was measured. Second. in-
creased skin reacrivjry ro recall antigen following cimeridine ad-
ministration increases 122-24). 
Int('restingly, activation of the immune system reactivity at a dose 
of BOO mg seems to be limited to the T cdl s. becaus(' the immuno-
globulin production . reflecting B cdl acrivarion. is unaltered. In 
contrast to the cited srudies, we performed cimetidine administra-
tion only for a shorr tiIDe period; therefore. our results may reflecr 
th t" shon durat.ion of intake. An additional explanation for the dis-
ctepant results may be that we performed this scudy on healthy 
persons. in conrrast to orher studies. 
""hat is striking, however, is the connecrion between cimeridine 
effect and t.he imrnllnosystem when administe ring 1,600 mg cime-
tidinc per day. In this case the significamly increased mitogen-in-
duc.ed lymphocyte proliferation is integrated into rhe rransfonna-
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rion of the immune process from macrophage to antibody; all 
participating cel ls, i.e., macrophages. CD2. CD4, and B Iympbo-
cvtes are increased in number. 
. The function of B lymphocytes was also significand y increased 
after cirnetidine treatment. which can be deduced from rh e in-
creased concentrations of immunogJobulins. Possibly the function 
of macrophages also increases because of cimetidine, because Mer-
ety a nd Falus {2S] also found a signi6canr cimetidine-linked (antag-
onism of histamine-induced suppression) increase of complement 
factor C3 concentration. 
B eside the fact that differem cimetidine doses influence different 
lymphocyte phenorypes, it was also detected that the duration of 
eife,cts is extended with high-cimetidine doses. PHA- and PWM-
induced proliferation is significantly enhanced for a period of 14 d 
and the relative number of CD4 lymphocytes is significantly en-
hanced for a pe riod of21 d. Our results show that ahhough different 
cim cridine doses obviously influence different cell rypcs,the cel lular 
mechanism is the same, namel y, a mitoge.n-induced lymphocyte 
prolifera tion and an increased incorpora tion of Mg and Zn ill lym-
phocytes. This m igh t be a starting point for a more derailed evalua-
tion of tbe mechanisms of cimetidinc eJfectiveness. On the other 
hand. o ur resulrs .g ive rise to an investigation about whether the 
dose-dependent effect of histamine can be antagonized b y a mecha-
ni sm chat causes low cimetidine concentrations co increase the Con 
A~indl1ced proliferation. according to a theory by Oh and Nakano 
{261. High-dose intake provokes an immune respome in blood. 
whereas skin test reactivity does not show this effect. The evidence 
of skin resting is certainly limited due to the observation of disso-
ciated immune reactivity in both compartments. 
We ,hank Mrs, £. Bnmdt:rt o,ld MrJ. Futile 1M exc~lIetll u!r/lni(Qf ossiJtollu. 
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